CDC25C and acute myeloid leukemia: The direct inhibitors have not been investigated in clinical trials (or are in the early stages of clinical trials) and their pharmacokinetic properties have to be better characterized, but despite this they should be regarded as promising therapeutic agents in human AML because they offer the possibility to target several proteins, including various CDC25 isoforms as well as several kinases, through the administration of single pharmacological agents.